Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT00243867 2025-08-01

Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer

Phase 3 Completed

518 enrolled 16 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04924101 2025-07-23

KEYNOTE-B99

Phase 2 Completed

126 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT02358031 2025-07-18

MK-3475-048

Phase 3 Completed

882 enrolled 50 charts 1 FDA

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Head and Neck Neoplasms

NCT05005728 2025-07-17

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

72 enrolled

Genitourinary

Prostatic Neoplasms

NCT03574779 2025-07-15

OPAL

Phase 2 Completed

77 enrolled 8 charts

Gynecologic

Ovarian Neoplasms

NCT04489888 2025-06-19

MK-3475-B10

Phase 4 Completed

101 enrolled 14 charts

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT06087289 2025-06-08

KANDOVA

Phase 1/2 Completed

18 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04774380 2025-05-23

LUMINANCE

Phase 3 Completed

152 enrolled 17 charts

Thoracic

Small Cell Lung Carcinoma

NCT00516724 2025-04-11

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

Phase 1 Completed

189 enrolled

BreastGynecologic

Triple Negative Metastatic Breast Cancer

NCT05834348 2025-03-30

DELINOR

Completed

5,279 enrolled 10 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02922764 2025-03-26

A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer

Phase 1 Completed

146 enrolled

GynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma

NCT02098343 2025-03-17

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

Phase 1/2 Completed

247 enrolled 15 charts

Gynecologic

Ovarian Neoplasms, Recurrence

Clinical Trials

KEYLYNK-009

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

KEYLYNK-008

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

LEAP-006

MK-7684A-007

KEYNOTE-826

SKYSCRAPER-06

LEAP-001

SKYSCRAPER-02

CheckMate 6DW

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy

Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM

A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC

CheckMate 816

A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors

CheckMate 9LA

Morpheus Lung

A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

APHINITY

CUPISCO

IMpassion132

CheckMate 227

MK-3475-522

KEYVIBE-001

MK-4830-001

A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

MK-4830-002

Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

LEAP-006

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

KEYVIBE-005

Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer

KEYNOTE-B99

MK-3475-048

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

OPAL

MK-3475-B10

KANDOVA

LUMINANCE

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

DELINOR

A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246